Wealthstream Advisors Inc. Decreases Holdings in Eli Lilly and Company (NYSE:LLY)

Wealthstream Advisors Inc. lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.7% in the fourth quarter, Holdings Channel reports. The firm owned 1,270 shares of the company’s stock after selling 62 shares during the period. Wealthstream Advisors Inc.’s holdings in Eli Lilly and Company were worth $980,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Northwest Capital Management Inc boosted its holdings in Eli Lilly and Company by 9.5% in the 4th quarter. Northwest Capital Management Inc now owns 219 shares of the company’s stock worth $169,000 after buying an additional 19 shares during the last quarter. Crestwood Advisors Group LLC lifted its position in shares of Eli Lilly and Company by 1.0% in the fourth quarter. Crestwood Advisors Group LLC now owns 36,050 shares of the company’s stock valued at $27,830,000 after acquiring an additional 364 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Eli Lilly and Company by 32.1% in the fourth quarter. IFP Advisors Inc now owns 13,991 shares of the company’s stock worth $10,806,000 after acquiring an additional 3,400 shares during the last quarter. Hardman Johnston Global Advisors LLC increased its position in shares of Eli Lilly and Company by 100.3% during the fourth quarter. Hardman Johnston Global Advisors LLC now owns 18,723 shares of the company’s stock worth $14,454,000 after purchasing an additional 9,376 shares in the last quarter. Finally, RWC Asset Management LLP raised its stake in Eli Lilly and Company by 12.2% in the 4th quarter. RWC Asset Management LLP now owns 487 shares of the company’s stock valued at $376,000 after purchasing an additional 53 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of several recent research reports. Bank of America reaffirmed a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Wolfe Research initiated coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price on the stock. Truist Financial upped their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Finally, Wells Fargo & Company reduced their price objective on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,000.28.

Eli Lilly and Company Trading Up 0.1 %

NYSE LLY opened at $874.12 on Monday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock has a market capitalization of $828.82 billion, a P/E ratio of 74.65, a PEG ratio of 1.40 and a beta of 0.42. The firm’s 50-day moving average is $801.33 and its two-hundred day moving average is $847.66. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company declared that its board has initiated a stock buyback program on Monday, December 9th that permits the company to buyback $15.00 billion in outstanding shares. This buyback authorization permits the company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.69%. Eli Lilly and Company’s payout ratio is presently 51.24%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.